Sysmex Co. (OTCMKTS:SSMXY - Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 28,200 shares, a decline of 46.5% from the April 30th total of 52,700 shares. Based on an average daily volume of 165,000 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the company's shares are short sold.
Sysmex Trading Down 2.3%
SSMXY stock traded down $0.38 during midday trading on Tuesday, hitting $16.43. The company had a trading volume of 59,984 shares, compared to its average volume of 71,334. The stock has a market cap of $10.34 billion, a price-to-earnings ratio of 29.34 and a beta of 1.22. Sysmex has a 52 week low of $14.38 and a 52 week high of $22.00. The company has a current ratio of 3.19, a quick ratio of 2.42 and a debt-to-equity ratio of 0.11. The stock's 50 day moving average price is $18.08 and its 200 day moving average price is $18.66.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.04). The company had revenue of $958.89 million for the quarter, compared to the consensus estimate of $991.22 million. As a group, equities research analysts expect that Sysmex will post 0.57 earnings per share for the current fiscal year.
Sysmex Company Profile
(
Get Free Report)
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Further Reading
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
